Targeted alpha therapy with 212Pb or 225Ac: Change in RBE from daughter migration

The favorable outcome of the phase 3, ALSYMPCA (Alpharadin in Symptomatic Prostate Cancer Patients) trial has highlighted the use of -emitting radionuclides for therapy [1]. In this context, 223Ra, a calcium mimetic, was used in the treatment of patients with castration-resistant prostate cancer and bone metastases. Although this treatment exploits the natural accumulation of 223Ra in areas of increased bone turnover in bone metastases, active targeting of cancer cells or tumor vasculature can also be achieved.
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research